582 related articles for article (PubMed ID: 22156660)
21. Proarrhythmic potential of antimicrobial agents.
Simkó J; Csilek A; Karászi J; Lorincz I
Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
[TBL] [Abstract][Full Text] [Related]
22. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
[TBL] [Abstract][Full Text] [Related]
23. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
24. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
25. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
26. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
Shantsila E; Watson T; Lip GY
Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
[TBL] [Abstract][Full Text] [Related]
28. Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses.
Joy JP; Coulter CV; Duffull SB; Isbister GK
Clin Pharmacol Ther; 2011 Aug; 90(2):243-5. PubMed ID: 21716272
[TBL] [Abstract][Full Text] [Related]
29. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
[TBL] [Abstract][Full Text] [Related]
30. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
31. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.
Anderson ME; Mazur A; Yang T; Roden DM
J Pharmacol Exp Ther; 2001 Mar; 296(3):806-10. PubMed ID: 11181910
[TBL] [Abstract][Full Text] [Related]
32. Blockade of HERG channels by HIV protease inhibitors.
Anson BD; Weaver JG; Ackerman MJ; Akinsete O; Henry K; January CT; Badley AD
Lancet; 2005 Feb 19-25; 365(9460):682-6. PubMed ID: 15721475
[TBL] [Abstract][Full Text] [Related]
33. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
35. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Frothingham R
Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
[TBL] [Abstract][Full Text] [Related]
36. Pentamidine-induced long QT syndrome and block of hERG trafficking.
Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
[TBL] [Abstract][Full Text] [Related]
37. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
38. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
Hondeghem LM
J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced QT-interval prolongation and recurrent torsade de pointes in a child with heterotaxy syndrome and KCNE1 D85N polymorphism.
Lin L; Horigome H; Nishigami N; Ohno S; Horie M; Sumazaki R
J Electrocardiol; 2012; 45(6):770-3. PubMed ID: 22999324
[TBL] [Abstract][Full Text] [Related]
40. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
